JP2006500009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500009A5 JP2006500009A5 JP2004520117A JP2004520117A JP2006500009A5 JP 2006500009 A5 JP2006500009 A5 JP 2006500009A5 JP 2004520117 A JP2004520117 A JP 2004520117A JP 2004520117 A JP2004520117 A JP 2004520117A JP 2006500009 A5 JP2006500009 A5 JP 2006500009A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- agent
- amino acid
- medicament
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 23
- 210000004027 cell Anatomy 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 8
- 239000003053 toxin Substances 0.000 claims 8
- 231100000765 toxin Toxicity 0.000 claims 8
- 108700012359 toxins Proteins 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000002254 cytotoxic agent Substances 0.000 claims 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 230000001293 nucleolytic effect Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39499802P | 2002-07-09 | 2002-07-09 | |
| PCT/US2003/021606 WO2004004662A2 (en) | 2002-07-09 | 2003-07-08 | Compositions and methods for the diagnosis and treatment of tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006500009A JP2006500009A (ja) | 2006-01-05 |
| JP2006500009A5 true JP2006500009A5 (pt) | 2006-08-24 |
Family
ID=30115799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004520117A Withdrawn JP2006500009A (ja) | 2002-07-09 | 2003-07-08 | 腫瘍の診断と治療のための組成物と方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20060062727A1 (pt) |
| EP (1) | EP1572091A4 (pt) |
| JP (1) | JP2006500009A (pt) |
| AU (1) | AU2003249014B2 (pt) |
| CA (1) | CA2491488A1 (pt) |
| IL (1) | IL165950A0 (pt) |
| WO (1) | WO2004004662A2 (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| DK2345671T3 (en) * | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체 |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| JP4860703B2 (ja) | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | 最適化された抗ｃｄ３０抗体 |
| PT2059536E (pt) | 2006-08-14 | 2014-04-14 | Xencor Inc | Anticorpos otimizados que visam cd19 |
| WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| SI2235059T1 (sl) | 2007-12-26 | 2015-06-30 | Xencor, Inc. | Fc variante s spremenjeno vezjo na fcrn |
| US9274119B2 (en) * | 2008-01-11 | 2016-03-01 | The University Of Tokyo | Anti-CLDN6 antibody |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| MX354359B (es) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
| HUE056217T2 (hu) | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében |
| BR112019001989A2 (pt) | 2016-08-02 | 2019-08-20 | Visterra Inc | polipeptídeos projetados e usos dos mesmos |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ261571A (en) * | 1993-02-04 | 1997-03-24 | Denzyme Aps | Producing correctly folded proteins using multiple denaturation and renaturation cycles |
| IT1318691B1 (it) * | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche del gruppo 2 di dermatophagoides. |
| AU2003221886A1 (en) * | 2002-04-12 | 2003-10-27 | The Board Of Trustees Of The University Of Arkansas | Beta2-MICROGLOBILIN (Beta2m) AND ANTI-Beta2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS |
-
2003
- 2003-07-08 CA CA002491488A patent/CA2491488A1/en not_active Abandoned
- 2003-07-08 JP JP2004520117A patent/JP2006500009A/ja not_active Withdrawn
- 2003-07-08 AU AU2003249014A patent/AU2003249014B2/en not_active Expired - Fee Related
- 2003-07-08 EP EP03763455A patent/EP1572091A4/en not_active Withdrawn
- 2003-07-08 WO PCT/US2003/021606 patent/WO2004004662A2/en active Search and Examination
- 2003-07-08 US US10/521,053 patent/US20060062727A1/en not_active Abandoned
-
2004
- 2004-12-23 IL IL16595004A patent/IL165950A0/xx unknown
-
2006
- 2006-09-29 US US11/537,292 patent/US20090181014A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006500009A5 (pt) | ||
| Christiansen et al. | Biological impediments to monoclonal antibody–based cancer immunotherapy | |
| JP2021184721A5 (pt) | ||
| CA2618681A1 (en) | Identification and engineering of antibodies with variant fc regions and methods of using same | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| HRP20170879T1 (hr) | Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena | |
| JP2016529215A5 (pt) | ||
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| JP2008537673A5 (pt) | ||
| JP2009507470A5 (pt) | ||
| JP2007532139A5 (pt) | ||
| JP2009518039A5 (pt) | ||
| JP2009502139A5 (pt) | ||
| JP2018520091A5 (pt) | ||
| JP2015502397A5 (pt) | ||
| JP2014070074A5 (pt) | ||
| JP2010516708A5 (pt) | ||
| JP2010535713A5 (pt) | ||
| JP2010531140A5 (pt) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2009545325A5 (pt) | ||
| CA2691075C (en) | Treatment of tumors using specific anti-l1 antibody | |
| JP2024016024A5 (pt) | ||
| JPWO2019224718A5 (pt) | ||
| JP2019524640A5 (pt) |